Curia´s Patented Process For Intermediates Useful For Deucravacitinib

This paper examines recent advances in the synthesis of Deucravacitinib, a TYK2 inhibitor used in the treatment of plaque psoriasis, and reviews persistent challenges associated with producing its key intermediates. For years, published routes have relied on chlorination and amidation sequences that deliver only modest yields and require purification techniques — such as NMP/iPrOH recrystallization or column chromatography — that introduce practical and regulatory limitations. Prior reports note that “the methods disclosed in the prior art…give rise to the desired product in low yield,” and commonly used purification approaches may leave behind unacceptable levels of residual solvents or prove too costly and inefficient for large-scale manufacturing.

Against this backdrop, the paper describes a newly patented approach developed by scientists at Curia, centered on a strategically designed intermediate of formula (I). The discussion highlights how this intermediate can be accessed more efficiently through hydrolysis of an ester precursor, providing a streamlined entry point into the broader synthetic sequence. The narrative also emphasizes Curia’s focus on industrial feasibility, regulatory alignment, and practical manufacturability — factors that are essential for processes intended to support commercial-scale pharmaceutical production.